Next generation drug connectivity mapping for acquiring therapeutic agents to differentially regulate myelination  

作　　者：Kasum Azim Andrea Domenico Rivera Arthur Morgan Butt 

机构地区：[1]Department of Neurology,Medical Faculty,Heinrich-Heine-University,Düsseldorf,Germany [2]Institute of Biomedical and Biomolecular Sciences,School of Pharmacy and Biomedical Science,University of Portsmouth,St Michael’s Building,White Swan Road,Portsmouth,UK [3]Section of Human Anatomy,Department of Neuroscience,University of Padua,Padua,Italy

出　　处：《Neural Regeneration Research》2023年第4期797-798,共2页中国神经再生研究（英文版）

摘　　要：The need for new therapeutic approaches:Conventional drug discovery is a lengthy and expensive process,taking decades and billions of dollars to get a drug from bench to bedside.Much of the costs incurred are at the pre-clinical stages,between drug design and synthesis to delineating the cellular“Mechanisms of Action”(MoA).Notably,there is a very high risk of failure,and only a very small proportion of therapeutic agents reach later-phase clinical trials.Accordingly,drug repositioning has become a valuable strategy aimed at fast-tracking treatments into clinical use and improving the chances of therapeutic success.A novel addition to this approach is connectivity mapping,which defines cell-specific transcriptional responses to small molecules in disease-dependent contexts.This commentary outlines how some of the latest innovations in connectivity mapping can be exploited for drug repurposing.

关 键 词：CONNECTIVITY DOLLAR THERAPEUTIC 

分 类 号：R741[医药卫生—神经病学与精神病学]